US FDA approves over-the-counter Tylenol combination pill…

The U.S. Food and Drug Administration (FDA) has approved a new nonprescription pain relief pill that combines Kenvue's Tylenol with naproxen, providing up to 12 hours of relief for conditions such as headaches and muscle aches. This fixed-dose pill is suitable for adults and children aged 12 and older, containing 325 mg of Tylenol and 110 mg of naproxen sodium. The approval supports a federal initiative to enhance access to safe medications. However, Tylenol has faced scrutiny over alleged links to autism when used during pregnancy, resulting in legal actions against Kenvue, which is set to be acquired by Kimberly-Clark for over $40 billion.

Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv

Tylenol is displayed for sale in Washington

Tylenol is displayed for sale behind a locked anti-theft barrier at a pharmacy in Washington, D.C., U.S., September 5, 2025. REUTERS/Jonathan Ernst/File Photo Purchase Licensing Rights, opens new tab

Companies
Kenvue Inc

Kimberly-Clark Corp

U.S. Food and Drug Administration

July 24 (Reuters) - The U.S. Food and Drug Administration on Friday approved a nonprescription, fixed-dose pill that combines Kenvue's (KVUE.N), opens new tab Tylenol with the nonsteroidal anti-inflammatory ‌drug naproxen for up to 12 hours of pain relief.

Here are some details:

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

The pill can be used by adults and children aged 12 and older for headaches, back pain, muscle aches, ⁠toothaches, menstrual cramps and minor arthritis pain.
The FDA said the approval aligns with Trump's "The Great Healthcare Plan," a federal effort to make more verified safe pharmaceutical drugs available for over-the-counter purchase.
Each pill contains 325 milligrams of Tylenol and 110 milligrams of naproxen sodium.
Tylenol has been under scrutiny after U.S. health ‌officials ⁠raised concerns about an alleged link between Tylenol use during pregnancy and autism. There is no firm scientific evidence of such a link.
The debate has also triggered legal ⁠action, as Texas sued Kenvue over alleged failures to warn pregnant consumers, and a U.S. appeals court this month ⁠revived more than 500 private lawsuits making similar claims.
Kenvue agreed last November to be acquired by Kleenex ⁠tissue maker Kimberly-Clark (KMB.O), opens new tab for more than $40 billion. The transaction is expected to close this year.